Truist raises Incyte stock target to USD 115
Published on 10/15/2026 at 20:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and trading dates
- Truist lifted its Incyte target to USD 115 on October 14, 2026.
- Incyte is scheduled to report third-quarter results on October 29, 2026.
- Incyte stock costs EUR 101.28 at Lang & Schwarz on October 15, 2026 at 8:09 p.m. CEST, 11.04 percent below the 52-week high.
- Incyte has a P/E ratio of 14.47 and a market capitalization of USD 23.0 billion as of October 15, 2026.
Truist raised its Incyte target from USD 105 to USD 115 on October 14, 2026, while keeping a Hold rating, according to Markets Insider. Incyte stock was at EUR 101.28 at Lang & Schwarz on October 15, 2026 at 8:09 p.m. CEST.
Results date is October 29
Incyte is estimated to report third-quarter 2026 results on October 29, 2026, before the US market opens, with an 8:00 a.m. ET conference call, according to MarketBeat. The date gives the next defined event for the stock after the recent analyst revision.
Price stays below yearly high
The euro quote sits within a 52-week range of EUR 73.40 to EUR 113.85, with the current price 11.04 percent below the upper end. The range was reported for October 14, 2026, while the Lang & Schwarz price is dated October 15, 2026. Incyte also gained 1.77 percent on Nasdaq on October 15, 2026, reaching USD 113.55 from a previous close of USD 111.57.
Historical fiscal year 2025 figures put revenue at USD 5.1 billion, net income at USD 1.3 billion and net margin at 25.0 percent, according to Alysly. The figures provide a longer-term operating reference without replacing the upcoming third-quarter report.
Valuation and market scale
Incyte had a P/E ratio of 14.47 and a market capitalization of USD 23.0 billion as of October 15, 2026. The dividend yield was 0.00 percent. Truist's Hold rating leaves the higher target as a valuation reference rather than a change in recommendation.
Comparison with peers
Incyte (Nasdaq, USD): 1.77 percent, P/E 14.47, market capitalization USD 23.0 billion
AbbVie (NYSE, USD): 1.47 percent, P/E 80.58, market capitalization USD 505.2 billion
Gilead Sciences (Nasdaq, USD): 3.52 percent, , market capitalization USD 197.1 billion
Trading context
The next scheduled catalyst is the October 29 earnings release, while the current euro quote remains below the 52-week high and above the reported 52-week low. The further course of trading is shown by the continuously updated real-time quote of Incyte stock.
Incyte stock market facts
- Company: Incyte Corporation
- ISIN: US45337C1027
- Ticker: INCY
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 8:09 p.m. CEST): EUR 101.28
- Market capitalization: USD 23.0 billion (as of October 15, 2026)
- 52-week range: EUR 73.40-EUR 113.85 (as of October 14, 2026)
- Sector / Industry: Health care / Biotechnology
Market context: Market report Nasdaq Composite.
